Expectations trend
FY2028 · fiscal year ending 2028-09-30 · fmp
ESCO Technologies Inc. (ESE)
NYSEIndustrialsHardware, Equipment & PartsSnapshot 2026-11-04
$225.79-5.87%
Close 2026-11-05 · 1-day change
NYSEIndustrialsHardware, Equipment & PartsSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
10.62 → 10.94 EPS · FY ending Sep 30, 2028 · 3 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 3 to 3; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for ESE yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
EPS near $8.12 in FY26 | A primary condition in ESCO Technologies Inc.'s published investment case. The stated target is >= $8.0 and <= $8.25. | Broken | EPS falls below $8.0 in FY26 | Diluted EPS: $1.26 per share FY2026-Q3; GAAP. Published target: >= $8.0 and <= $8.25. Annual target cannot be compared with a quarterly or TTM observation. Aug 10, 20261.26 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-09-30 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 19, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
ESE is a growing industrial business with recent financial performance rated strong, rather than a turnaround. Its multi-year view is intact, though confidence is now medium and management execution on the Megger acquisition remains important.
The valuation is expensive versus peers, trading at a 17% premium, while the expectations gap is relatively small at 0.07. The evidence labels expectations as justified and fragility as low, but that leaves limited room for weaker results to be absorbed without challenging the thesis.
Near-term results have been strong: revenue increased across the first three quarters of 2026, and management raised full-year revenue and adjusted earnings guidance. The Megger acquisition was reported completed on October 2, after earlier plans for a fiscal 2027 close, while sector weakness and a possible guidance cut remain risks.
Over the next few quarters, the thesis hinges on continued revenue growth, better operating income and margins, and successful integration of Megger. Guidance cuts or weaker results from industrial bellwethers could weaken the sector backdrop, while continued strong reports and higher guidance from those companies would support it.
For the 1-to-3-year view, ESE’s operating progress supports an intact thesis, but its premium valuation and sector headwind make execution important. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| ESCO grows revenue about 19% yearly, helped by the Megger acquisition. |
| Intact |
| Acquisition fails or integration materially disrupts growth |
Acquisition completed 2026-10-01 vs target 'completed by next 4 quarters' News confirms ESCO completed Megger Group acquisition on Oct 1, 2026, aligning with growth strategy. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in a supplied disclosure. Management reported: “· Synergies: Through targeted collaboration between ESCO and Megger, the combination is expected to realize approximately $60 million in cost synergies within the first three years following closing.” “The addition of Megger is a major milestone in our strategy to build a scaled, differentiated, high-margin utility solutions platform,” said Bryan Sayler, President and Chief Executive Officer of ESCO Technologies.” Delivery assessment Nov 4, 2026 |
Operating income increase to at least $43.86M in Q2 FY26 | Operating income improved from $38M to $44M in recent quarters. | Intact | Operating income falls below $38.36M in Q2 FY26 | Operating income: $40.954M FY2026-Q3; GAAP. Published target: >= $43.86M. Target period is not explicitly aligned with this observation. Aug 10, 202640,954,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth near $1.32B in FY26 | A primary condition in ESCO Technologies Inc.'s published investment case. The stated target is >= $1.29B and <= $1.33B. | Broken | Revenue falls below $1.29B in FY26 | Revenue: $339.027M FY2026-Q3; GAAP. Published target: >= $1.29B and <= $1.33B. Annual target cannot be compared with a quarterly or TTM observation. Aug 10, 2026339,027,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$10.62 → $10.94 · observed estimates
$1.74B → $1.97B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-10-01 | $10.62 | $1,740,378,571 | 3 / 3 |
| 2026-10-02 | $10.62 | $1,740,378,571 | 3 / 3 |
| 2026-10-03 | $10.62 | $1,740,378,571 | 3 / 3 |
| 2026-10-04 | $10.62 | $1,740,378,571 | 3 / 3 |
| 2026-10-05 | $10.62 | $1,740,378,571 | 3 / 3 |
| 2026-10-06 | $10.62 | $1,740,378,571 | 3 / 3 |
| 2026-10-07 | $10.62 | $1,740,378,571 | 3 / 3 |
| 2026-10-08 | $10.62 | $1,740,378,571 | 3 / 3 |
| 2026-10-09 | $10.62 | $1,740,378,571 | 3 / 3 |
| 2026-10-10 | $10.62 | $1,740,378,571 | 3 / 3 |
| 2026-10-11 | $10.62 | $1,740,378,571 | 3 / 3 |
| 2026-10-12 | $10.62 | $1,740,378,571 | 3 / 3 |
| 2026-10-13 | $10.62 | $1,740,378,571 | 3 / 3 |
| 2026-10-14 | $10.62 | $1,740,378,571 | 3 / 3 |
| 2026-10-15 | $10.62 | $1,740,378,571 | 3 / 3 |
| 2026-10-16 | $10.62 | $1,740,378,571 | 3 / 3 |
| 2026-10-17 | $10.62 | $1,740,378,571 | 3 / 3 |
| 2026-10-18 | $10.62 | $1,740,378,571 | 3 / 3 |
| 2026-10-19 | $10.94 | $1,740,378,571 | 3 / 3 |
| 2026-10-20 | $10.94 | $1,740,378,571 | 3 / 3 |
| 2026-10-21 | $10.94 | $1,973,649,721 | 3 / 3 |
| 2026-10-22 | $10.94 | $1,973,649,721 | 3 / 3 |
| 2026-10-23 | $10.94 | $1,973,649,721 | 3 / 3 |
| 2026-10-24 | $10.94 | $1,973,649,721 | 3 / 3 |
| 2026-10-25 | $10.94 | $1,973,649,721 | 3 / 3 |
| 2026-10-26 | $10.94 | $1,973,649,721 | 3 / 3 |
| 2026-10-27 | $10.94 | $1,973,649,721 | 3 / 3 |
| 2026-10-28 | $10.94 | $1,973,649,721 | 3 / 3 |
| 2026-10-29 | $10.94 | $1,973,649,721 | 3 / 3 |
| 2026-10-30 | $10.94 | $1,973,649,721 | 3 / 3 |
| 2026-10-31 | $10.94 | $1,973,649,721 | 3 / 3 |
| 2026-11-01 | $10.94 | $1,973,649,721 | 3 / 3 |
| 2026-11-02 | $10.94 | $1,973,649,721 | 3 / 3 |
| 2026-11-03 | $10.94 | $1,973,649,721 | 3 / 3 |
| 2026-11-04 | $10.94 | $1,973,649,721 | 3 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.